We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
Read MoreHide Full Article
The ongoing M&A wave in the pharma/biotech sector gains further momentum from the significant rally in the share price movement of gene therapy company Audentes Therapeutics, Inc. earlier in the week. The stock’s impressive upsurge followed the Japanese company Astellas Pharma Inc’s announcement to acquire Audentes for a cash consideration of $60 per share or a total deal value of approximately $3 billion. The offer price represents a premium of 110% to Audentes’ closing share price of $28.61 on Dec 2, 2019.
It is interesting to note that attractive modest valuations on account of a disappointing run in 2018 rekindled interest in the ever-volatile biotech sector from the start of this year. Evidently, the spotlight is back on mergers & acquisitions. A slowdown in mature products due to increasing competition and the rise of biosimilars forced most pharma behemoths to target lucrative buyouts in the biotech space to bolster their pipelines. While oncology and immuno-oncology are the key areas of focus, companies targeting non-alcoholic steatohepatitis (NASH), rare diseases and candidates based on gene therapy also promise great potential, thereby making the respective areas profitable for investments.
Bristol-Myers Squibb Company (BMY - Free Report) , one of the largest pharma giants, acquired leading biotech company Celgene for a whopping $74 billion in what could be a major acquisition of recent times. Thereafter, a slew of deals was struck with most companies eyeing smaller entities with impressive pipelines, the latest being the Swiss pharma leader Novartis, which reached an agreement to acquire U.S.-based biopharmaceutical company, The Medicines Company, for $9.7 billion.
Earlier in the year, Roche (RHHBY - Free Report) announced that it will acquire gene therapy company Spark Therapeutics Inc. However, the buyout has been getting delayed, dampening hopes of investors.
Nevertheless, the recent acquisition announcement by Astellas brings the gene therapy space into prominence once again.
What is Gene Therapy?
Gene therapy enables to mitigate the adverse effects of a malfunctioning disease-causing gene. The therapy intends to add a functional gene to a person's system, replacing the malfunctioning one to cure diseases. The gene is delivered to a cell though a carrier known as vector. The therapy has a different approach from the traditional drug treatments as the underlying cause can be treated with it.
Gene therapy is set to become one of the most vital spaces with high prospects in the volatile biotech sector. The promising therapy is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, cancer among others.
Gene Therapy Companies in Focus
Given the potential of the therapy to treat complex diseases, the companies developing candidates using gene therapy are in focus. Let us consider a few players with promising drugs/candidates in their portfolios/pipelines as they appear attractive targets of acquisition:
uniQure N.V. (QURE - Free Report) is one of the most promising players in this space with a focused pipeline of innovative gene therapies for hemophilia B and Huntington’s disease. Etranacogene dezaparvovec is its lead gene therapy candidate and includes an AAV5 vector incorporating the Factor IX-Padua variant. The company is currently conducting a pivotal study in patients with severe and moderately-severe hemophilia B. The candidate is granted a Breakthrough Therapy Designation by the FDA. In early September 2019, the company completed patient enrollment in its HOPE-B pivotal study of etranacogene dezaparvovec for the treatment of patients with severe and moderately severe hemophilia B. uniQure expects to provide top-line Factor IX (FIX) activity data on all patients before the end of 2020 and submit a Biologics License Application (BLA) for the marketing authorization of etranacogene dezaparvovec in 2021.
Commercial-stage biopharmaceutical company Sarepta Therapeutics, Inc. (SRPT - Free Report) is focused on developing unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Its first commercial product Exondys 51 is indicated to address DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Sarepta is also developing gene therapies for treating Limb-girdle muscular dystrophy (LGMD) and central nervous system disorders including Mucopolysaccharidosis type IIIA (MPS IIIA) and Pompe Disease.
With a market cap of $8.3 billion, Sarepta has been on the radar for quite some time now.
BioMarin Pharmaceutical Inc. (BMRN - Free Report) develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. With a market cap of $14.6 billion, the company boasts an excellent portfolio of seven commercialized products and an impressive pipeline. It recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. BioMarin is on track to submit a BLA to the FDA by this year-end. The FDA granted valoctocogene roxaparvovec a Breakthrough Therapy designation. Valoctocogene roxaparvovec received an Orphan Drug tag from the FDA and the EMA.
Sangamo Therapeutics, Inc. (SGMO - Free Report) continues to advance its SB-525 hemophilia A gene therapy program. It is conducting a phase I/II Alta study, an open-label, ascending-dose clinical study to evaluate investigational SB-525 gene therapy for severe hemophilia A in collaboration with Pfizer IncThe FDA conferred a regenerative medicine advanced therapy or RMAT status on SB-525 gene therapy to treat severe hemophilia. This includes all the benefits of the fast track and breakthrough therapy designation programs including early interactions with the FDA. Sangamo is also evaluating its wholly-owned investigational ST-920 gene therapy for Fabry disease, an inherited metabolic disease. The FDA also granted Orphan Drug Designation to ST-920 for the treatment of Fabry disease. The company has a market cap of $1.36 billion.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
The ongoing M&A wave in the pharma/biotech sector gains further momentum from the significant rally in the share price movement of gene therapy company Audentes Therapeutics, Inc. earlier in the week. The stock’s impressive upsurge followed the Japanese company Astellas Pharma Inc’s announcement to acquire Audentes for a cash consideration of $60 per share or a total deal value of approximately $3 billion. The offer price represents a premium of 110% to Audentes’ closing share price of $28.61 on Dec 2, 2019.
It is interesting to note that attractive modest valuations on account of a disappointing run in 2018 rekindled interest in the ever-volatile biotech sector from the start of this year. Evidently, the spotlight is back on mergers & acquisitions. A slowdown in mature products due to increasing competition and the rise of biosimilars forced most pharma behemoths to target lucrative buyouts in the biotech space to bolster their pipelines. While oncology and immuno-oncology are the key areas of focus, companies targeting non-alcoholic steatohepatitis (NASH), rare diseases and candidates based on gene therapy also promise great potential, thereby making the respective areas profitable for investments.
Bristol-Myers Squibb Company (BMY - Free Report) , one of the largest pharma giants, acquired leading biotech company Celgene for a whopping $74 billion in what could be a major acquisition of recent times. Thereafter, a slew of deals was struck with most companies eyeing smaller entities with impressive pipelines, the latest being the Swiss pharma leader Novartis, which reached an agreement to acquire U.S.-based biopharmaceutical company, The Medicines Company, for $9.7 billion.
Earlier in the year, Roche (RHHBY - Free Report) announced that it will acquire gene therapy company Spark Therapeutics Inc. However, the buyout has been getting delayed, dampening hopes of investors.
Nevertheless, the recent acquisition announcement by Astellas brings the gene therapy space into prominence once again.
What is Gene Therapy?
Gene therapy enables to mitigate the adverse effects of a malfunctioning disease-causing gene. The therapy intends to add a functional gene to a person's system, replacing the malfunctioning one to cure diseases. The gene is delivered to a cell though a carrier known as vector. The therapy has a different approach from the traditional drug treatments as the underlying cause can be treated with it.
Gene therapy is set to become one of the most vital spaces with high prospects in the volatile biotech sector. The promising therapy is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, cancer among others.
Gene Therapy Companies in Focus
Given the potential of the therapy to treat complex diseases, the companies developing candidates using gene therapy are in focus. Let us consider a few players with promising drugs/candidates in their portfolios/pipelines as they appear attractive targets of acquisition:
uniQure N.V. (QURE - Free Report) is one of the most promising players in this space with a focused pipeline of innovative gene therapies for hemophilia B and Huntington’s disease. Etranacogene dezaparvovec is its lead gene therapy candidate and includes an AAV5 vector incorporating the Factor IX-Padua variant. The company is currently conducting a pivotal study in patients with severe and moderately-severe hemophilia B. The candidate is granted a Breakthrough Therapy Designation by the FDA. In early September 2019, the company completed patient enrollment in its HOPE-B pivotal study of etranacogene dezaparvovec for the treatment of patients with severe and moderately severe hemophilia B. uniQure expects to provide top-line Factor IX (FIX) activity data on all patients before the end of 2020 and submit a Biologics License Application (BLA) for the marketing authorization of etranacogene dezaparvovec in 2021.
With a market cap of $2.85 billion, this company is the front runner for a likely buyout. uniQure currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Commercial-stage biopharmaceutical company Sarepta Therapeutics, Inc. (SRPT - Free Report) is focused on developing unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Its first commercial product Exondys 51 is indicated to address DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Sarepta is also developing gene therapies for treating Limb-girdle muscular dystrophy (LGMD) and central nervous system disorders including Mucopolysaccharidosis type IIIA (MPS IIIA) and Pompe Disease.
With a market cap of $8.3 billion, Sarepta has been on the radar for quite some time now.
BioMarin Pharmaceutical Inc. (BMRN - Free Report) develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. With a market cap of $14.6 billion, the company boasts an excellent portfolio of seven commercialized products and an impressive pipeline. It recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. BioMarin is on track to submit a BLA to the FDA by this year-end. The FDA granted valoctocogene roxaparvovec a Breakthrough Therapy designation. Valoctocogene roxaparvovec received an Orphan Drug tag from the FDA and the EMA.
Sangamo Therapeutics, Inc. (SGMO - Free Report) continues to advance its SB-525 hemophilia A gene therapy program. It is conducting a phase I/II Alta study, an open-label, ascending-dose clinical study to evaluate investigational SB-525 gene therapy for severe hemophilia A in collaboration with Pfizer IncThe FDA conferred a regenerative medicine advanced therapy or RMAT status on SB-525 gene therapy to treat severe hemophilia. This includes all the benefits of the fast track and breakthrough therapy designation programs including early interactions with the FDA. Sangamo is also evaluating its wholly-owned investigational ST-920 gene therapy for Fabry disease, an inherited metabolic disease. The FDA also granted Orphan Drug Designation to ST-920 for the treatment of Fabry disease. The company has a market cap of $1.36 billion.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>